PROCEPT BioRobotics Corporation (PRCT) Fair Value 2026

PRCT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, PROCEPT BioRobotics Corporation (PRCT) trades at $20.83. QOC: 6.9/10. Value Trap Risk: 26/100 (LOW). 0/13 models active.

Key Facts

Ticker
PRCT
Price
$20.83
Quality Score
6.9/10
Value Trap Risk
26/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give PRCT?

0 Intrinsic Value Models vs. Current Price ($20.83)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is PROCEPT BioRobotics Corporation (PRCT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, PROCEPT BioRobotics Corporation currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PRCT?

0 of 13 models are currently active for PRCT. See which stocks rank higher →

How Does PRCT Rank in Medical Devices?

Among 159 Medical Devices stocks, PRCT ranks #52 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

As a healthcare company, PROCEPT BioRobotics Corporation operates in a sector where R&D productivity ratio is a critical driver of valuation. Investors evaluating PRCT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is PRCT a Value Trap?

CirclFi's Value Trap algorithm assigns PRCT a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for PROCEPT BioRobotics Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, PROCEPT BioRobotics Corporation's fundamental quality profile registers 6.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PRCT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy PROCEPT BioRobotics Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

MXCTMaxCyte, Inc.QOC 7.0CERSCerus CorporationQOC 6.9ESTAEstablishment Labs Holdings Inc.QOC 7.0CTKBCytek Biosciences, Inc.QOC 6.9MASS908 Devices Inc.QOC 7.1ATECAlphatec Holdings, Inc.QOC 6.9AIDX20/20 Biolabs, Inc.QOC 6.0ALURAllurion Technologies Inc.QOC 4.8ABTAbbott LaboratoriesQOC 8.8IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: MXCT · CERS · ESTA · CTKB · MASS · ATEC · AIDX · ALUR · ABT · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to PRCT?

7 companies across all industries closest to PRCT’s Quality of Company score of 6.9/10.

KVYOKlaviyo, Inc.QOC 6.9AMTDAMTD IDEA GroupQOC 6.9JRVRJames River Group Holdings, Inc.QOC 6.9CBATCBAK Energy Technology LimitedQOC 6.9CZRCaesars Entertainment, Inc.QOC 6.9STRSStratus Properties Inc.QOC 6.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KVYO · AMTD · JRVR · CBAT · CZR · STRS · NVDA

Where Does PRCT Sit in CirclFi's Medical Devices Rankings?

PRCT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About PROCEPT BioRobotics Corporation’s Valuation?

What is PROCEPT BioRobotics Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for PROCEPT BioRobotics Corporation (PRCT). The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PRCT overvalued or undervalued right now?

At $20.83, 0 of 0 active models suggest PRCT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits PROCEPT BioRobotics Corporation's business model in Medical Devices.

What does a Quality of Company score of 6.9 mean for PRCT?

PROCEPT BioRobotics Corporation's QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PRCT?

CirclFi analyzes PRCT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PRCT a value trap in 2026?

PROCEPT BioRobotics Corporation's Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns PROCEPT BioRobotics Corporation (PRCT) a Quality of Company score of 6.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PRCT/ · Methodology
Primary sources for this PRCT valuation
  • Financial statements: PROCEPT BioRobotics Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001588978) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PRCT as of ; valuations recomputed .